DK3124483T3 - Pyrazolaminopyrimidin-derivater som LRRK2-modulatorer - Google Patents
Pyrazolaminopyrimidin-derivater som LRRK2-modulatorer Download PDFInfo
- Publication number
- DK3124483T3 DK3124483T3 DK16180927.2T DK16180927T DK3124483T3 DK 3124483 T3 DK3124483 T3 DK 3124483T3 DK 16180927 T DK16180927 T DK 16180927T DK 3124483 T3 DK3124483 T3 DK 3124483T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyrazolaminopyrimidine
- derivatives
- lrrk2 modulators
- lrrk2
- modulators
- Prior art date
Links
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 title 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41227310P | 2010-11-10 | 2010-11-10 | |
US201161546613P | 2011-10-13 | 2011-10-13 | |
EP11782588.5A EP2638031B9 (en) | 2010-11-10 | 2011-11-09 | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3124483T3 true DK3124483T3 (da) | 2019-09-02 |
Family
ID=44983512
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16180927.2T DK3124483T3 (da) | 2010-11-10 | 2011-11-09 | Pyrazolaminopyrimidin-derivater som LRRK2-modulatorer |
DK11782588.5T DK2638031T3 (en) | 2010-11-10 | 2011-11-09 | PYRAZOLAMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11782588.5T DK2638031T3 (en) | 2010-11-10 | 2011-11-09 | PYRAZOLAMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS |
Country Status (28)
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2726465A1 (en) | 2011-05-23 | 2014-05-07 | Elan Pharmaceuticals Inc. | Inhibitors of lrrk2 kinase activity |
AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
US8791130B2 (en) * | 2011-11-29 | 2014-07-29 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 modulators |
US20140228384A1 (en) * | 2011-11-29 | 2014-08-14 | Genentech, Inc. | Assays and biomarkers for lrrk2 |
CA2850594C (en) * | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
ES2638595T3 (es) | 2011-11-29 | 2017-10-23 | Genentech, Inc. | Derivados de aminopirimidina como moduladores de LRRK2 |
BR112014012822A8 (pt) | 2011-11-30 | 2017-07-11 | Hoffmann La Roche | Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2 |
EP2844652B1 (en) * | 2012-05-03 | 2019-03-13 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
CN106279202A (zh) * | 2012-05-03 | 2017-01-04 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物 |
NZ702571A (en) | 2012-06-29 | 2017-02-24 | Pfizer | 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
WO2014060381A1 (de) | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
WO2014134772A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
KR102374178B1 (ko) | 2013-12-17 | 2022-03-14 | 메르크 파텐트 게엠베하 | 피루베이트 데히드로게나아제 키나아제의 저해제로서의 n1-(3,3,3-트리플루오로-2-히드록소-2-메틸프로피오닐)-피페리딘 유도체 |
JP6487921B2 (ja) | 2013-12-17 | 2019-03-20 | ファイザー・インク | LRRK2阻害薬としての新規の3,4−二置換−1H−ピロロ[2,3−b]ピリジンおよび4,5−二置換−7H−ピロロ[2,3−c]ピリダジン |
MX2016007898A (es) | 2013-12-20 | 2016-10-07 | Signal Pharm Llc | Compuestos diaminopirimidilo sustituidos, las composiciones de estos y los metodos de tratamiento con estos. |
ES2717757T3 (es) | 2014-01-29 | 2019-06-25 | Glaxosmithkline Ip Dev Ltd | Compuestos |
CN105940004B (zh) * | 2014-01-29 | 2018-02-02 | 葛兰素史密斯克莱知识产权发展有限公司 | 化合物 |
CA2943979A1 (en) * | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
US9859504B2 (en) * | 2014-03-31 | 2018-01-02 | Commonwealth Scientific And Industrial Research Organisation | Diamine compounds for phosphorescent diazaborole metal complexes and electroluminescent devices |
GB2538476B (en) * | 2014-05-08 | 2019-03-20 | Tosoh F Tech Inc | 5-(Trifluoromethyl)pyrimidine derivatives and method for producing same |
US10058559B2 (en) | 2014-05-15 | 2018-08-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
JP6262079B2 (ja) * | 2014-06-02 | 2018-01-17 | 東ソー・ファインケム株式会社 | 4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法 |
JP6431294B2 (ja) * | 2014-06-16 | 2018-11-28 | 東ソー・ファインケム株式会社 | 5−(トリフルオロメチル)ピリミジン誘導体及びその製造法 |
ES2699948T3 (es) | 2014-10-14 | 2019-02-13 | Sunshine Lake Pharma Co Ltd | Compuestos de heteroarilo sustituido y métodos de uso |
CN108137586B (zh) | 2015-09-14 | 2021-04-13 | 辉瑞大药厂 | 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物 |
WO2017087905A1 (en) * | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
EP3436443B1 (en) | 2016-03-29 | 2020-03-11 | Merck Patent GmbH | N1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase |
JP7028792B2 (ja) | 2016-04-28 | 2022-03-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピペリジニル誘導体 |
CR20220182A (es) | 2016-06-16 | 2022-06-15 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos (divisional 2018-592) |
CN106588885B (zh) * | 2016-11-10 | 2019-03-19 | 浙江大学 | 2-取代芳环-嘧啶类衍生物及制备和应用 |
CN106588884B (zh) * | 2016-11-10 | 2019-04-09 | 浙江大学 | 2-多取代芳环-嘧啶类衍生物及制备和医药用途 |
WO2018155947A1 (ko) | 2017-02-24 | 2018-08-30 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
US20200157081A1 (en) * | 2017-05-24 | 2020-05-21 | Denali Therapeutics Inc. | Compounds, compositions and methods |
WO2019012093A1 (en) * | 2017-07-14 | 2019-01-17 | Glaxosmithkline Intellectual Property Development Limited | INHIBITORS OF REACTION KINASE 2 RICH IN LEUCINE |
EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE |
KR20200089713A (ko) | 2017-11-21 | 2020-07-27 | 데날리 테라퓨틱스 인크. | 피리미디닐아미노-피라졸 화합물의 다형체와 고체 형태, 그리고 생산 방법 |
MX2020006641A (es) | 2017-12-20 | 2021-01-08 | Denali Therapeutics Inc | Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol. |
WO2019160037A1 (ja) * | 2018-02-14 | 2019-08-22 | 国立大学法人 東京大学 | 酸ハロゲン化物による化合物の製造方法 |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
AR118641A1 (es) * | 2019-04-11 | 2021-10-20 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
CN114126408A (zh) * | 2019-05-31 | 2022-03-01 | 戴纳立制药公司 | 嘧啶基氨基-吡唑化合物的改良释放配制品和治疗方法 |
KR20220151617A (ko) * | 2020-03-06 | 2022-11-15 | 내셔날 헬스 리서치 인스티튜트 | 피리미딘 화합물 및 이의 약학적 용도 |
CA3172750A1 (en) | 2020-03-23 | 2021-09-30 | Ge Hyeong Lee | Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same |
KR102342803B1 (ko) | 2020-03-23 | 2021-12-24 | 환인제약 주식회사 | 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물 |
CN116685325A (zh) | 2020-10-20 | 2023-09-01 | 豪夫迈·罗氏有限公司 | Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法 |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
WO2022197577A1 (en) * | 2021-03-17 | 2022-09-22 | Merck Sharp & Dohme Llc | Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
AU2022243600A1 (en) * | 2021-03-26 | 2023-10-12 | Sumitomo Pharma Oncology, Inc. | Alk-5 inhibitors and uses thereof |
WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
WO2023174946A1 (en) | 2022-03-15 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Early and non-invasive method for assessing a subject's risk of having parkinson's disease |
WO2023224894A1 (en) * | 2022-05-20 | 2023-11-23 | Merck Sharp & Dohme Llc | Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
CN115819405A (zh) * | 2022-12-20 | 2023-03-21 | 沪渝人工智能研究院 | 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用 |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL313973A1 (en) | 1993-10-12 | 1996-08-05 | Du Pont Merck Pharma | 1 n-alkyl-n-arylopyrimidin amines and their derivatives |
RU2153494C2 (ru) | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
KR100643419B1 (ko) | 1998-03-27 | 2006-11-10 | 얀센 파마슈티카 엔.브이. | Hiv를 억제하는 피리미딘 유도체 |
US6458823B1 (en) | 1998-06-08 | 2002-10-01 | Wyeth | Diaminopyrazoles |
US6172222B1 (en) | 1998-06-08 | 2001-01-09 | American Home Products Corporation | Diaminopyrazoles |
BRPI9915552B8 (pt) | 1998-11-10 | 2021-05-25 | Janssen Pharmaceutica Nv | pirimidinas inibidoras da reprodução do hiv |
PL366110A1 (en) | 1999-08-13 | 2005-01-24 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
SK285240B6 (sk) | 1999-09-24 | 2006-09-07 | Janssen Pharmaceutica N. V. | Antivírusové prostriedky |
US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
EP1282606B1 (en) | 2000-05-08 | 2015-04-22 | Janssen Pharmaceutica NV | Hiv replication inhibiting pyrimidines and triazines |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CA2422371C (en) | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002046184A1 (en) | 2000-12-05 | 2002-06-13 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
US20030105090A1 (en) | 2000-12-21 | 2003-06-05 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
IL156306A0 (en) | 2000-12-21 | 2004-01-04 | Glaxo Group Ltd | Pyrimidineamines as angiogenesis modulators |
WO2002092573A2 (en) | 2001-05-16 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
PL367130A1 (en) | 2001-05-29 | 2005-02-21 | Schering Aktiengesellschaft | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
HUP0402352A2 (hu) | 2001-06-19 | 2005-02-28 | Bristol-Myers Squibb Co. | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények |
WO2003000186A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel phenylamino-pyrimidines and uses thereof |
CA2451128A1 (en) | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
UY27487A1 (es) | 2001-10-17 | 2003-05-30 | Boehringer Ingelheim Pharma | Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación |
AU2002367172A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
JP2005526765A (ja) * | 2002-03-11 | 2005-09-08 | シエーリング アクチエンゲゼルシャフト | Cdk−阻害性2−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用 |
US7288547B2 (en) | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
MXPA05005547A (es) | 2002-11-28 | 2005-07-26 | Schering Ag | Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos. |
WO2004067516A1 (en) | 2003-01-30 | 2004-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
JP4648324B2 (ja) | 2003-05-21 | 2011-03-09 | バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト | ヨードピラゾリルカルボキシアニリド類 |
WO2005009977A1 (en) | 2003-07-15 | 2005-02-03 | Neurogen Corporation | Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands |
WO2005012298A1 (en) | 2003-07-30 | 2005-02-10 | Cyclacel Limited | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
KR101201603B1 (ko) * | 2003-07-30 | 2012-11-14 | 리겔 파마슈티칼스, 인크. | 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물 |
EP1663242B1 (en) | 2003-08-07 | 2011-04-27 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
MXPA06013165A (es) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
EP1763514A2 (en) | 2004-05-18 | 2007-03-21 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
WO2006014482A1 (en) | 2004-07-08 | 2006-02-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of pkc-theta |
US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
WO2006028833A1 (en) | 2004-09-01 | 2006-03-16 | Rigel Pharmaceuticals, Inc. | Synthesis of 2,4-pyrimidinediamine compounds |
WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
EP1814878B1 (en) | 2004-11-24 | 2012-01-04 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
BRPI0517426A (pt) | 2004-12-17 | 2008-10-07 | Astrazeneca Ab | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente |
JP5208516B2 (ja) * | 2004-12-30 | 2013-06-12 | エグゼリクシス, インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
DE102005008310A1 (de) | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
EP1705177A1 (en) | 2005-03-23 | 2006-09-27 | Schering Aktiengesellschaft | N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
US20080194606A1 (en) * | 2005-05-05 | 2008-08-14 | Astrazeneca | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer |
US7491732B2 (en) | 2005-06-08 | 2009-02-17 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
WO2006135915A2 (en) | 2005-06-13 | 2006-12-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
JP5118029B2 (ja) | 2005-06-14 | 2013-01-16 | タイゲン バイオテクノロジー カンパニー,リミテッド | ピリミジン化合物 |
US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
WO2007023382A2 (en) | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
CA2621057A1 (en) | 2005-09-07 | 2007-03-15 | Laboratoires Serono S.A. | Ikk inhibitors for the treatment of endometriosis |
EP1934200A1 (en) * | 2005-09-15 | 2008-06-25 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
DE102005048072A1 (de) | 2005-09-24 | 2007-04-05 | Bayer Cropscience Ag | Thiazole als Fungizide |
WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
US8623887B2 (en) | 2006-05-15 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Compounds |
DE102006027156A1 (de) | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
CA2655315A1 (en) | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-aminoalkyleneaminopyrimidines |
US20080131937A1 (en) | 2006-06-22 | 2008-06-05 | Applera Corporation | Conversion of Target Specific Amplification to Universal Sequencing |
JP2009545598A (ja) | 2006-08-01 | 2009-12-24 | プリーシス・ファーマシューティカルズ・インコーポレイテッド | P38キナーゼ阻害剤 |
DE102006041382A1 (de) | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
US20080194575A1 (en) | 2006-10-04 | 2008-08-14 | Naiara Beraza | Treatment for non-alcoholic-steatohepatitis |
MX2009005649A (es) | 2006-11-27 | 2009-06-08 | Ares Trading Sa | Tratamiento para mieloma multiple. |
EP2091918B1 (en) | 2006-12-08 | 2014-08-27 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
GB0625196D0 (en) | 2006-12-18 | 2007-01-24 | 7Tm Pharma As | Modulators of cannabinoid receptor |
CA2670645A1 (en) | 2006-12-19 | 2008-07-03 | Genentech, Inc. | Pyrimidine kinase inhibitors |
EP1939185A1 (de) | 2006-12-20 | 2008-07-02 | Bayer Schering Pharma Aktiengesellschaft | Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs |
US20100144706A1 (en) | 2006-12-22 | 2010-06-10 | Boehringer Ingelheim International Gmbh | Compounds |
EP2121633A2 (en) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
DE102007010801A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
WO2008132502A1 (en) | 2007-04-25 | 2008-11-06 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer |
KR20100020454A (ko) | 2007-06-08 | 2010-02-22 | 바이엘 크롭사이언스 소시에떼아노님 | 살진균제 헤테로사이클릴-피리미디닐-아미노 유도체 |
CA2693594A1 (en) | 2007-07-17 | 2009-01-22 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
US8563542B2 (en) | 2007-09-28 | 2013-10-22 | Cyclacel Limited | Pyrimidine derivatives as protein kinase inhibitors |
EP2197853B1 (en) | 2007-10-09 | 2011-11-09 | Dow AgroSciences LLC | Insecticidal pyrimidinyl aryl hydrazones |
MY152948A (en) | 2007-11-16 | 2014-12-15 | Incyte Corp | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
JP2011505407A (ja) | 2007-12-03 | 2011-02-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン |
KR20100098521A (ko) | 2007-12-07 | 2010-09-07 | 노파르티스 아게 | 피라졸 유도체 및 그의 사이클린 의존성 키나제 억제제로서의 용도 |
CN102007124B (zh) | 2008-02-15 | 2014-06-18 | 里格尔制药公司 | 嘧啶-2-胺化合物及其作为jak激酶抑制剂的用途 |
CL2009000600A1 (es) | 2008-03-20 | 2010-05-07 | Bayer Cropscience Ag | Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas. |
US20100056524A1 (en) | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
DK2300013T3 (en) | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
UY31929A (es) | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
US8716486B2 (en) | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
KR20110046514A (ko) | 2008-07-31 | 2011-05-04 | 제넨테크, 인크. | 피리미딘 화합물, 조성물 및 사용 방법 |
US20110159019A1 (en) | 2008-09-01 | 2011-06-30 | Akira Tanaka | 2,4-diaminopyrimidine compound |
KR20110049905A (ko) | 2008-09-03 | 2011-05-12 | 바이엘 크롭사이언스 아게 | 4-알킬-치환된 디아미노피리미딘 |
WO2010025850A1 (de) | 2008-09-03 | 2010-03-11 | Bayer Cropscience Ag | Heterozyklisch substituierte anilinopyrimidine als fungizide |
US20100144722A1 (en) | 2008-09-03 | 2010-06-10 | Dr. Reddy's Laboratories Ltd. | Novel heterocyclic compounds as gata modulators |
EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
JP2012501978A (ja) | 2008-09-03 | 2012-01-26 | バイエル・クロップサイエンス・アーゲー | 殺菌剤としてのヘテロ環置換アニリノピリミジン類 |
WO2010038081A2 (en) | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
UY32240A (es) | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
WO2010080712A2 (en) | 2009-01-06 | 2010-07-15 | Dana Farber Cancer Institute | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
US20110071158A1 (en) | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
CA2757188A1 (en) * | 2009-03-30 | 2010-10-07 | Astellas Pharma Inc. | Pyrimidine compound |
EP2419423A1 (en) | 2009-04-14 | 2012-02-22 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
US20120142667A1 (en) | 2009-06-10 | 2012-06-07 | Nigel Ramsden | Pyrimidine derivatives as zap-70 inhibitors |
EP2440548A1 (en) | 2009-06-10 | 2012-04-18 | Abbott Laboratories | 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors |
TW201103904A (en) | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
CA2763720A1 (en) | 2009-06-18 | 2010-12-23 | Cellzome Limited | Sulfonamides and sulfamides as zap-70 inhibitors |
WO2010146133A1 (en) | 2009-06-18 | 2010-12-23 | Cellzome Limited | Heterocyclylaminopyrimidines as kinase inhibitors |
SG179172A1 (en) | 2009-09-16 | 2012-04-27 | Avila Therapeutics Inc | Protein kinase conjugates and inhibitors |
EP2483254B1 (en) | 2009-09-29 | 2014-08-13 | Glaxo Group Limited | Novel compounds |
US8629132B2 (en) | 2009-11-13 | 2014-01-14 | Genosco | Kinase inhibitors |
SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
CA2797947C (en) * | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
US8791130B2 (en) * | 2011-11-29 | 2014-07-29 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 modulators |
ES2638595T3 (es) * | 2011-11-29 | 2017-10-23 | Genentech, Inc. | Derivados de aminopirimidina como moduladores de LRRK2 |
AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
CA2850594C (en) * | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
BR112014012822A8 (pt) * | 2011-11-30 | 2017-07-11 | Hoffmann La Roche | Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2 |
-
2011
- 2011-11-09 HU HUE11782588A patent/HUE037844T2/hu unknown
- 2011-11-09 AR ARP110104181A patent/AR083813A1/es not_active Application Discontinuation
- 2011-11-09 SG SG2013021100A patent/SG189043A1/en unknown
- 2011-11-09 PL PL11782588T patent/PL2638031T3/pl unknown
- 2011-11-09 LT LTEP16180927.2T patent/LT3124483T/lt unknown
- 2011-11-09 TW TW100140970A patent/TW201302733A/zh unknown
- 2011-11-09 SI SI201131772T patent/SI3124483T1/sl unknown
- 2011-11-09 NO NO11782588A patent/NO2638031T3/no unknown
- 2011-11-09 HU HUE16180927A patent/HUE046617T2/hu unknown
- 2011-11-09 US US13/292,668 patent/US8815882B2/en active Active
- 2011-11-09 JP JP2013538172A patent/JP5986094B2/ja active Active
- 2011-11-09 LT LTEP11782588.5T patent/LT2638031T/lt unknown
- 2011-11-09 MX MX2013005199A patent/MX2013005199A/es active IP Right Grant
- 2011-11-09 DK DK16180927.2T patent/DK3124483T3/da active
- 2011-11-09 ES ES16180927T patent/ES2746134T3/es active Active
- 2011-11-09 KR KR1020137014605A patent/KR101566091B1/ko active IP Right Grant
- 2011-11-09 AU AU2011328139A patent/AU2011328139A1/en not_active Abandoned
- 2011-11-09 EP EP11782588.5A patent/EP2638031B9/en active Active
- 2011-11-09 EP EP16180927.2A patent/EP3124483B1/en active Active
- 2011-11-09 RS RS20191033A patent/RS59106B1/sr unknown
- 2011-11-09 CA CA2812669A patent/CA2812669C/en active Active
- 2011-11-09 ES ES11782588.5T patent/ES2653967T3/es active Active
- 2011-11-09 RS RS20171211A patent/RS56583B1/sr unknown
- 2011-11-09 CN CN201180053793.8A patent/CN103313978B/zh active Active
- 2011-11-09 EP EP19184916.5A patent/EP3590933B1/en active Active
- 2011-11-09 PT PT117825885T patent/PT2638031T/pt unknown
- 2011-11-09 SI SI201131377T patent/SI2638031T1/en unknown
- 2011-11-09 PL PL16180927T patent/PL3124483T3/pl unknown
- 2011-11-09 BR BR112013011600-5A patent/BR112013011600B1/pt active IP Right Grant
- 2011-11-09 CA CA3017869A patent/CA3017869C/en active Active
- 2011-11-09 WO PCT/EP2011/069696 patent/WO2012062783A1/en active Application Filing
- 2011-11-09 PT PT161809272T patent/PT3124483T/pt unknown
- 2011-11-09 DK DK11782588.5T patent/DK2638031T3/en active
-
2013
- 2013-03-14 IL IL225234A patent/IL225234A0/en unknown
- 2013-05-03 MA MA35869A patent/MA34644B1/fr unknown
- 2013-05-08 EC ECSP13012611 patent/ECSP13012611A/es unknown
-
2014
- 2014-01-16 HK HK14100468.7A patent/HK1187605A1/xx unknown
-
2016
- 2016-08-04 JP JP2016153608A patent/JP6298115B2/ja active Active
-
2017
- 2017-12-27 CY CY20171101349T patent/CY1120073T1/el unknown
- 2017-12-29 HR HRP20172006TT patent/HRP20172006T1/hr unknown
-
2018
- 2018-02-22 JP JP2018029462A patent/JP6524284B2/ja active Active
-
2019
- 2019-10-02 HR HRP20191781TT patent/HRP20191781T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3124483T3 (da) | Pyrazolaminopyrimidin-derivater som LRRK2-modulatorer | |
HRP20160771T1 (hr) | Derivati aminopirimidina kao modulatori za lrrk2 | |
DK2411393T3 (da) | Kondenserede pyrimidin-dionderivater som TRPA1-modulatorer | |
DK2421825T3 (da) | Azetidinyldiamider som monoacylglycerollipase-inhibitorer | |
DK2590974T3 (da) | Tetrahydropyridopyrimidinderivater | |
DK2616102T3 (da) | Prodrugs, som omfatter et exendin-linker-konjugat | |
CO6890099A2 (es) | Nuevos derivados dihidroquinolina-2-ona | |
DK3103797T3 (da) | 2,5-dioxoimidazolidin-1-yl-3-phenylurinstofderivater som formylpeptidreceptor-lignende-1- (fprl-1) receptormodulatorer | |
DK2411397T3 (da) | Isothiazol-pyrimidindionderivater som modulatorer af TRPA1 | |
DK2678329T3 (da) | Triazolopyridinforbindelser som pim-kinase-hæmmere | |
DK3070091T3 (da) | Benzodioxolderivater som phosphodiesterasehæmmere | |
DK2513105T3 (da) | 2-arylimidazolderivater som pde10a-enzyminhibitorer | |
DK2938615T3 (da) | Imidazopyridazin-derivater som GABAA-receptormodulatorer | |
DK2513106T3 (da) | Heteroaromatiske aryltriazol-derivater som pde10a-enzyminhibitorer | |
DE102011075103A8 (de) | Photodetektor | |
BR112014000015A2 (pt) | formulação | |
DK2252609T3 (da) | Pyridin-2-yl-derivater som immunomodulerende midler | |
UA21334S (uk) | Цукерка | |
CO6960557A2 (es) | Derivados de 2-yodo-imidazol | |
BR112013013837A2 (pt) | derivados de substituição de imidazoquinolina | |
DK2635269T3 (da) | Kombinationspræparat | |
DK2609083T3 (da) | Substituerede 2-oxy-quinolin-3-carboxamider som KCNQ2/3 modulatorer | |
DK2655518T3 (da) | Dispersions-azo-farvestoffer | |
SMT201500067B (it) | Derivati di acilbenzene | |
DK2367787T3 (da) | 3-phenyl-3-methoxypyrrolidinderivater som modulatorer af kortikal katekolaminerg neurotransmission |